Treatment of Recurrent Primary or Secondary Central Nervous System (CNS) Lymphoma With ALIMTA (Pemetrexed)
Status:
Completed
Trial end date:
2015-09-01
Target enrollment:
Participant gender:
Summary
The purpose of this research study is to determine the safety of the study drug pemetrexed,
and the highest dose of this drug that can be given to people safely. Another goal of this
research study is to gain information about how the body handles pemetrexed and how
pemetrexed may work to treat the participant's lymphoma in the nervous system. Pemetrexed
(also known as Alimta) has been approved by the FDA for the treatment of some lung cancers
and has been shown to be effective in laboratory studies. Information from these studies
suggests that pemetrexed may help to treat patients with either primary or secondary central
nervous system lymphoma.
Phase:
Phase 1
Details
Lead Sponsor:
Massachusetts General Hospital
Collaborators:
Beth Israel Deaconess Medical Center Dana-Farber Cancer Institute Eli Lilly and Company